Innate Pharma (IPHA): Company Future Sales Volume

Innate Pharma S.A. (IPHA) target sales levels reflect a trend driven by the delegation of testing to external centers while maintaining full patent control. The value of 0.00 determines the current magnitude of this metric. Business growth relies on partnerships with pharma behemoths to combat tumors. However, stringent FDA and EMA oversight, combined with exclusive rights to NK cells, create a significant barrier to entry for new players.

Company Revenue Forecast: Innate Pharma S.A. (IPHA) for 07/04/2022 - 11/14/2026

IPHA (Innate Pharma SA): analytical breakdowns and indicator data

- stock value and consensus price forecast:

Price Chart Innate Pharma S.A.|IPHA - Consensus Target

- stock exchange capitalization data:

Market Valuation Innate Pharma SA|IPHA - Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Innate Pharma|IPHA - Accounting Capitalization|Market Value to Book Value Ratio innate-pharma.com|IPHA - Company Assets

- company liabilities and liquidity data:

Total Debt to Equity Ratio Innate Pharma S.A.|IPHA - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Innate Pharma, S.A.|IPHA - Company Cumulative Indebtedness|Debts to Book Capitalization Innate Pharma SA|IPHA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Innate Pharma|Quick Liquidity innate-pharma.com

- company profitability and valuation multiples indicators:

IPHA - Final Profit|Projected Future Earnings Innate Pharma S.A.|IPHA - P/E Multiple|Future Price to Earnings Innate Pharma|IPHA - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio Innate Pharma SA|IPHA - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Innate Pharma|IPHA - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months innate-pharma.com|IPHA - Earnings per share growth this year|Net earnings per share growth forecast for next year Innate Pharma S.A.

- sales revenue and business income indicators:

IPHA - Company Sales Volume|Projected Sales Volume Innate Pharma S.A.|IPHA - P/S Multiple|Forward Price-to-Revenue Multiple Innate Pharma SA

Summary company analysis:Innate Pharma S.A.

This metric measures the expected revenue by separating actual market potential from management's declarations, allowing the investor to determine the extent of the asset's overvaluation. By analyzing the sales target of Innate Pharma S.A. (IPHA), one can assess the degree to which current licensing revenues from global antibody development partners confirm the sustainability of the Innate Pharma S.A. (IPHA) business model and its ability to scale R&D resources.

Direct competitors